CalciMedica (NASDAQ:CALC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $16.00 price objective on the stock.
CalciMedica Trading Down 0.9 %
NASDAQ:CALC opened at $2.20 on Tuesday. CalciMedica has a 12 month low of $1.91 and a 12 month high of $6.27. The company has a market cap of $29.66 million, a PE ratio of -2.04 and a beta of 1.18. The company has a 50 day simple moving average of $2.78 and a two-hundred day simple moving average of $3.46.
Institutional Trading of CalciMedica
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CALC. Atria Investments Inc increased its position in CalciMedica by 136.5% in the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after buying an additional 15,296 shares in the last quarter. Geode Capital Management LLC raised its position in shares of CalciMedica by 51.2% during the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after buying an additional 22,525 shares during the last quarter. PVG Asset Management Corp purchased a new stake in CalciMedica in the 3rd quarter worth $67,000. Corient Private Wealth LLC purchased a new stake in shares of CalciMedica in the fourth quarter worth about $135,000. Finally, Renaissance Technologies LLC bought a new position in shares of CalciMedica during the 4th quarter valued at approximately $153,000.
About CalciMedica
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Featured Stories
- Five stocks we like better than CalciMedica
- What Are the U.K. Market Holidays? How to Invest and Trade
- Mediterranean Growth Monster: CAVA Keeps Surging—Buy the Dip?
- 3 Small Caps With Big Return Potential
- Is the S&P 500 Ready to Rally? A $1.8M Bet on SPY Says Yes
- High Flyers: 3 Natural Gas Stocks for March 2022
- Consumer Spending Is Slowing—But These Stocks Will Still Thrive
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
